Health Canada has authorised Vyvanse (lisdexamphetamine dimesylate), the first and only, chewable tablet for the treatment of attention deficit/hyperactivity disorder

Takeda

10 July 2019 - Vyvanse offers an additional option for patients who prefer the convenience of a chewable tablet, or who have difficulty swallowing medication.

Takeda Canada announced today that Health Canada has authorized a chewable tablet of Vyvanse (lisdexamfetamine dimesylate). This is the first and only chewable treatment for patients with attention deficit/hyperactivity disorder aged six and older.

Vyvanse chewable tablets are also indicated for the treatment of moderate to severe binge eating disorder in adults aged 18 and older.

Read Takeda press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Outcome , Medicine , Canada , Paediatrics